HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Despotis, G. J. Articles by Lappas, D. G. Search for Related Content PubMed PubMed Citation Articles by Despotis, G. J. Articles by Lappas, D. G.

Ann Thorac Surg 1995;59:106-111
© 1995 The Society of Thoracic Surgeons

Effect of Aprotinin on Activated Clotting Time, Whole Blood and Plasma Heparin Measurements

Departments of Anesthesiology, Internal Medicine, Pathology, and Surgery, Washington University School of Medicine, and Departments of Internal Medicine and Pathology, St. Louis University School of Medicine, St. Louis, Missouri

Accepted for publication September 7, 1994.

Twenty cardiac surgical patients requiring cardiopulmonary bypass were enrolled in this study designed to evaluate the effect of aprotinin on activated clotting time (kaolin and celite), whole blood, and laboratory-based plasma (anti-Xa) heparin measurements. Whole blood heparin measurements were not different (p = 0.98) between aprotinin-treated (3.2 ± 2.8 U/mL) and control (3.2 ± 3.0 U/mL) specimens. Plasma anti-Xa heparin measurements were also not different (p = 0.95) between aprotinin-treated (2.7 ± 2.5 U/mL) and control (2.8 ± 2.5 U/mL) specimens. The relationship between whole blood (plasma equivalent) and plasma heparin measurements was similar (p = 0.1) in the presence (slope, 1.04; r² = 0.89) or absence (slope, 1.11; r² = 0.89) of aprotinin. In contrast to weak correlations between celite (r = 0.50) or kaolin (r = 0.53) activated clotting time values, whole blood heparin measurements correlated well (r = 0.93) with plasma heparin measurements during cardiopulmonary bypass in the presence of aprotinin. These findings indicate that whole blood heparin measurements are unaffected by aprotinin and correlate well with plasma anti-Xa heparin measurements even in the presence of aprotinin. Therefore, the automated protamine titration assay can be used to monitor accurately heparin concentrations in patients receiving aprotinin.

This article has been cited by other articles:

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				P D Raymond, M J Ray, S N Callen, and N A Marsh Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time Perfusion, September 1, 2003; 18(5): 269 - 276. [Abstract] [PDF]

				G. J. Despotis, J. H. Joist, and L. T. Goodnough Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes Clin. Chem., September 1, 1997; 43(9): 1684 - 1696. [Abstract] [Full Text] [PDF]

				G. J. Despotis, A. L. Alsoufiev, E. Spitznagel, L. T. Goodnough, and D. G. Lappas Response of Kaolin ACT to Heparin: Evaluation With an Automated Assay and Higher Heparin Doses Ann. Thorac. Surg., March 1, 1996; 61(3): 795 - 799. [Abstract] [Full Text]

				L. T. Goodnough, G. J. Despotis, C. W. Hogue Jr, and T. B. Ferguson Jr On the Need for Improved Transfusion Indicators in Cardiac Surgery Ann. Thorac. Surg., August 1, 1995; 60(2): 473 - 480. [Abstract] [Full Text]